🟢 Strong Evidence
A multicenter randomized controlled trial published in The Lancet Respiratory Medicine has demonstrated that sitafloxacin monotherapy achieves non-inferiority to the standard two-drug regimen of doxycycline plus rifampicin for treating acute uncomplicated brucellosis, while offering a superior tolerability and safety profile. This finding may reshape clinical practice for a disease that affects approximately 500,000 people annually, primarily in livestock-endemic regions across Central Asia, the Middle East, North Africa, and Mediterranean countries.
Key takeaways
- Sitafloxacin monotherapy achieved non-inferiority endpoints compared to doxycycline–rifampicin combination therapy in acute uncomplicated brucellosis
- Sitafloxacin demonstrated superior tolerability with fewer adverse events and improved patient compliance through single-agent dosing
- The trial enrolled patients across multiple centers, strengthening generalizability to diverse clinical settings in endemic regions
- A simpler one-drug regimen could reduce treatment costs and improve adherence in resource-limited healthcare systems
Study at a Glance
| Source | The Lancet Regional Health – Western Pacific |
| Study type | Multicenter randomized controlled trial (non-inferiority design) |
| Primary outcome | Clinical cure or improvement at 6 weeks post-treatment |
| Study arms | Sitafloxacin monotherapy vs. doxycycline + rifampicin combination |
| Publication | The Lancet Regional Health – Western Pacific, 2026 |
Brucellosis global burden and geographic distribution
Estimated annual case incidence by endemic region, highlighting areas where simplified treatment regimens could have greatest public health impact
Source: WHO Global Health Observatory, 2026 Brucellosis Epidemiology Report | Georgian Medical Journal News
From dual therapy to single-agent regimen: clinical implications
Brucellosis is a bacterial zoonotic infection caused by Brucella species, typically transmitted through contact with infected livestock or consumption of unpasteurized dairy products. Until now, the standard treatment for acute uncomplicated disease has involved a 6-week course of doxycycline combined with rifampicin—a regimen that, while effective, requires patients to manage two medications simultaneously, each with distinct dosing schedules and potential drug interactions.
The trial evaluated sitafloxacin, a fluoroquinolone antibiotic, as a potential single-agent alternative. According to The Lancet Regional Health – Western Pacific trial data, sitafloxacin monotherapy was non-inferior to standard dual therapy on the primary endpoint of clinical cure or improvement at six weeks post-treatment. Notably, patients receiving sitafloxacin reported fewer episodes of gastrointestinal disturbance, hepatic enzyme elevation, and photosensitivity—common adverse effects of doxycycline—and did not experience the drug-drug interactions associated with rifampicin coadministration. This safety advantage carries particular significance in endemic regions where patients often have limited access to frequent laboratory monitoring.
The non-inferiority design employed in this trial is methodologically rigorous for evaluating whether a new regimen performs at least as well as the established standard. By pre-specifying a non-inferiority margin based on clinical judgment and prior data, researchers ensured that any conclusion of equivalence was statistically meaningful, not merely a result of insufficient power to detect true differences.
Simplifying treatment burden in resource-limited settings
One of the trial’s most significant implications concerns medication adherence and healthcare cost reduction. In many endemic regions—particularly in the Middle East, Central Asia, and North Africa—patients often face barriers to completing lengthy multidrug courses, including inconsistent drug supply, cost constraints, and limited capacity for therapeutic drug monitoring. A single-agent regimen addresses these barriers directly.
Simplification from two to one medication reduces pharmacy burden, decreases the cumulative cost of therapy (one drug rather than two), and eliminates the need to counsel patients on complex dosing schedules and drug-interaction avoidance. This is particularly relevant in pastoral communities in endemic regions where brucellosis remains occupationally common and where healthcare infrastructure may be geographically dispersed. Improved adherence through simplified regimens is associated with better clinical outcomes and reduced recurrence rates, a relationship well-documented in infectious disease treatment literature.
Furthermore, the favorable tolerability profile observed with sitafloxacin—including reduced hepatotoxicity and gastrointestinal side effects—may improve patients’ ability to remain compliant without interrupting treatment due to intolerable adverse effects. This is particularly important in populations with high baseline rates of malnutrition or concurrent infections, where hepatic tolerance of doxycycline may be compromised.
Fluoroquinolones in infectious disease: safety considerations and surveillance
While the trial demonstrated non-inferiority and superior tolerability of sitafloxacin, the broader use of fluoroquinolones as first-line agents for bacterial infections remains a subject of clinical debate. The US Food and Drug Administration (FDA) has previously issued warnings regarding fluoroquinolone-associated adverse effects, including tendinopathy, peripheral neuropathy, and central nervous system effects, which typically occur with prolonged or repeated exposure. However, these data predominantly derive from studies of older fluoroquinolones and from populations receiving extended courses for chronic infections.
Sitafloxacin is a newer-generation fluoroquinolone with a different pharmacokinetic profile and preclinical data suggesting an improved safety margin. The trial’s safety data align with these preclinical expectations, though it is important that post-marketing surveillance systems in countries where brucellosis is endemic continue to monitor for rare adverse events as the agent’s use scales. Real-world safety registries, particularly in countries like Georgia, Turkey, and those across Central Asia where brucellosis remains endemic, will be essential for confirming long-term safety in diverse populations.
Implications for brucellosis management guidelines and future research
This trial may prompt infectious disease societies and WHO guideline committees to reassess standard treatment recommendations for acute uncomplicated brucellosis. If the findings are confirmed in real-world implementation cohorts and across diverse geographic and demographic settings, sitafloxacin could become a preferred option for patients with intolerance to doxycycline or for those in settings where medication adherence is a primary concern.
Future research should extend these findings to special populations not fully represented in the trial—including pregnant women (for whom doxycycline is typically avoided), pediatric patients, and those with renal or hepatic impairment. Additionally, cost-effectiveness analyses comparing sitafloxacin to standard regimens in low- and middle-income countries will inform policymakers’ decisions about formulary inclusion and reimbursement. Given that brucellosis frequently occurs as occupational disease in livestock workers with limited access to healthcare, trials in real-world endemic settings will be equally important as carefully controlled clinical trials.
Sitafloxacin monotherapy achieved non-inferiority to doxycycline–rifampicin for acute uncomplicated brucellosis while demonstrating superior tolerability and safety in a multicenter randomized controlled trial, offering potential for simplified treatment regimens in endemic regions.
— The Lancet Regional Health – Western Pacific (2026)
What this means
Frequently asked questions
Is sitafloxacin safe for all patients with brucellosis?
The trial demonstrated non-inferiority and favorable tolerability in adults with acute uncomplicated brucellosis. However, fluoroquinolones are contraindicated in pregnancy and typically avoided in pediatric patients due to potential effects on cartilage development. Additional research in these populations is needed before sitafloxacin can be recommended for pregnant women or children.
How much does sitafloxacin cost compared to doxycycline–rifampicin?
Cost comparisons were not detailed in the trial publication. However, eliminating one drug from the regimen typically reduces total medication cost. Policymakers in endemic regions should conduct formal pharmacoeconomic analyses to determine whether sitafloxacin’s price justifies formulary inclusion from a healthcare system perspective.
What should clinicians do if patients have fluoroquinolone allergy or intolerance?
The doxycycline–rifampicin combination remains an established and effective alternative. For patients with documented fluoroquinolone hypersensitivity or severe prior adverse reactions, the standard regimen should be continued. Individual patient factors—hepatic function, renal function, and comedications—should guide the choice between regimens.
The publication of this trial in The Lancet Regional Health – Western Pacific represents an important step forward in optimizing brucellosis treatment for populations where the disease remains endemic. As antimicrobial stewardship becomes increasingly central to global health strategy, the ability to offer effective single-agent therapy with reduced adverse effects and simplified logistics could meaningfully improve health outcomes in some of the world’s most economically vulnerable regions. Regulators, clinicians, and public health authorities in brucellosis-endemic countries should now engage in collaborative dialogue to evaluate whether and how sitafloxacin can be integrated into national treatment guidelines.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
